SAN DIEGO, Sept. 1, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief
Executive Officer Saundra Pelletier
will present and host one-on-one meetings at two upcoming investor
conferences as follows:
H.C. Wainwright
23rd Annual Global Investment Conference
|
|
|
Format:
|
Corporate
presentation
|
Date:
|
Monday, September 13,
2021
|
Time:
|
7:00 a.m. ET (4:00
a.m. PT)
|
|
|
Morgan Stanley
Virtual Global Healthcare Conference
|
|
|
Format:
|
Fireside
chat
|
Date:
|
Tuesday, September
14, 2021
|
Time:
|
12:30 – 1:00 p.m. ET
(9:30 -10:00 a.m. PT)
|
Webcasts of both events will be available through the Events
section of the Evofem website at
https://evofem.investorroom.com/events for 30 days.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing
innovative products to address unmet needs in women's sexual
and reproductive health, including hormone-free, woman-controlled
contraception and protection from certain sexually transmitted
infections (STIs). The Company launched its first FDA-approved
commercial product, Phexxi® (lactic acid,
citric acid and potassium bitartrate), in the United
States in September 2020. The Company is evaluating lead
product candidate EVO100 for the prevention of urogenital
Chlamydia trachomatis and Neisseria gonorrhoeae
infection in women in the ongoing Phase 3 clinical
trial, 'EVOGUARD.' For more information, please visit
evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-investor-conferences-301367047.html
SOURCE Evofem Biosciences, Inc.